Samatasvir
Alternative Names: IDX-18719; IDX-719; MK-1894Latest Information Update: 10 Oct 2023
Price :
$50 *
At a glance
- Originator Idenix Pharmaceuticals
- Developer Johnson & Johnson Innovative Medicine; Merck & Co
- Class Antivirals; Benzimidazoles; Carbamates; Imidazoles; Pyrrolidines; Thiophenes
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 01 Apr 2015 Merck and Janssen complete the phase II HELIX-1 trial in Hepatitis C (Combination therapy, Treatment-naive) in USA (NCT01852604)
- 20 Feb 2015 Discontinued - Phase-I/II for Hepatitis C in USA (PO) (Merck & Co, pipeline, February 2015)